Funds to support MIAtek® technology platform development
Paris, August 25, 2011 – Magnisense, a developer of next generation bioassays for human and animal diagnostics, food safety and environmental protection, announced today that it has completed a new round of financing raising a total of €1 million from its current shareholders, who once again, confirmed their faith in the MIAtek® technology as well as their strong commitment towards MAGNISENSE. This new round of financing provides the Magnisense SE with sufficient resources to sustain its program through 2012.
About Magnisense : www.magnisense.com
Magnisense was incorporated in 2004 and has been based in Paris and San Francisco since 2007 and 2009, respectively. The company develops and markets next-generation magnetic bioassays which improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing. The assays are based on a technological breakthrough: the use of magnetic beads as markers. The magnetic signal is not perturbed by the surrounding environment, which enables more sensitive, reproducible detection than can be achieved with conventional enzymatic or fluorescent labels. The Magnisense technologies enable the detection and accurate quantification of one or more biological targets in large sample volumes. Magnisense is developing two rapid test formats with a single dose, producing objective, quantifiable and traceable results via a portable reader, for different application areas:
Press and Analysts Contacts : + 1 408 666 76 39 hayat.el-yousfi@magnisense.com |